Drug Overview

Fruquintinib is a highly selective and potent medication used to treat advanced colorectal cancer. It belongs to a modern group of medicines known as Targeted Therapy. In the medical field, it is often called a “Smart Drug” because it is designed to find and block specific signals that tumors use to survive and grow, rather than attacking the entire body like traditional chemotherapy.

This medication has become a vital option for patients who have already tried other standard treatments. By focusing on the tumor’s blood supply, fruquintinib helps slow down the spread of cancer and can extend the lives of patients with metastatic disease.

Generic Name: Fruquintinib
US Brand Names: Fruzaqla
Drug Class: Kinase Inhibitor; Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitor
Route of Administration: Oral (Capsule taken by mouth)
FDA Approval Status: FDA Approved

What Is It and How Does It Work? (Mechanism of Action)

To understand how this Smart Drug works, imagine a tumor is like a tiny, growing city. To survive and expand, this city needs a constant supply of food and oxygen. It gets these by building its own network of new “pipelines”—which are actually blood vessels. This process is called angiogenesis.

At the molecular level, fruquintinib works as a “pipeline blocker”:

Spotting the Antennas: Cancer cells send out a protein called VEGF. This protein looks for special antennas on the surface of blood vessel cells called VEGFR-1, -2, and -3.
Blocking the Signal: Fruquintinib travels through the bloodstream and sits directly on these VEGFR antennas. It acts like a cap, preventing the VEGF protein from “plugging in.”
Stopping the Growth: Because the signal is blocked, the internal “wiring” of the cell (signaling pathways like the MAP kinase pathway) is turned off.
Starving the Tumor: Without these signals, the tumor cannot build new blood vessels. The existing vessels may even shrink. Without a fresh blood supply, the tumor starves, stops growing, and its spread is slowed down.

FDA Approved Clinical Indications

Fruquintinib is specifically approved for patients with advanced stages of cancer that have spread to other parts of the body.

Oncological Uses

Metastatic Colorectal Cancer (mCRC): For adult patients who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if medically appropriate, an anti-EGFR therapy.

Non-Oncological Uses

None. This medication is strictly used for the treatment of cancer.

Dosage and Administration Protocols

Fruquintinib is taken as a capsule at home. It is important to follow a specific “on and off” schedule to give the body time to rest.

Protocol Detail	Standard Recommendation
Standard Dose	5 mg daily.
Schedule	3 weeks “on” (taking the drug) followed by 1 week “off” (no drug).
Administration	Taken once daily, with or without food, at the same time each day.
Renal Insufficiency	No dose adjustment is usually needed for mild to moderate kidney issues.
Hepatic Insufficiency	No dose adjustment for mild liver issues; use with caution in moderate liver disease.

Clinical Efficacy and Research Results

Recent clinical data (from the FRESCO and FRESCO-2 trials, 2020–2025) has shown that fruquintinib is effective in patients who had very few options left.

Overall Survival: In the global FRESCO-2 trial, patients taking fruquintinib lived significantly longer than those taking a placebo. The numerical data showed a median overall survival of 7.4 months for fruquintinib compared to 4.8 months for the control group.
Progression-Free Survival: The drug effectively doubled the time patients lived without their cancer getting worse. The median time was 3.7 months for fruquintinib versus 1.8 months for the placebo.
Disease Control: Approximately 56% of patients achieved “disease control,” meaning their tumors either shrank or stayed the same size for a period of time.

Safety Profile and Side Effects

Because fruquintinib affects blood vessels, it can cause specific side effects related to blood pressure and skin.

Black Box Warning:

Fruquintinib does not currently have an FDA Black Box Warning. However, it carries serious warnings for severe hypertension (high blood pressure) and severe bleeding.

Common Side Effects (>10%)

Hypertension: High blood pressure is the most common side effect.
Hand-Foot Skin Reaction: Redness, pain, or swelling on the palms of the hands and soles of the feet.
Fatigue: Feeling unusually tired or weak.
Diarrhea: Frequent or loose stools.
Abdominal Pain: Stomach aches or discomfort.
Hypothyroidism: Low thyroid hormone levels.

Serious Adverse Events

Gastrointestinal Perforation: A rare but serious hole in the wall of the stomach or intestines.
Severe Bleeding (Hemorrhage): Dangerous bleeding in the brain or digestive tract.
Posterior Reversible Encephalopathy Syndrome (PRES): A rare brain condition causing headaches, seizures, and confusion.

Management Strategies

For High Blood Pressure: Your doctor will check your blood pressure weekly. You may need to start or adjust blood pressure medicine.
For Hand-Foot Reaction: Use thick, fragrance-free moisturizers and avoid hot water on your hands and feet.

Research Areas

Fruquintinib is a major focus in Combination Immunotherapy research. Scientists are currently testing if blocking blood vessel growth with fruquintinib can make “checkpoint inhibitors” (a type of immunotherapy) work better. The theory is that by normalizing the blood vessels around a tumor, the body’s natural killer T-cells can enter the tumor more easily to destroy it. Studies are also ongoing to see if this drug can help in gastric (stomach) and lung cancers.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Blood Pressure Check: To ensure your baseline pressure is normal.
Urine Test: To check for protein in the urine (proteinuria).
Thyroid Function Test: To check your hormone levels.
Liver and Kidney Panels: Standard blood work to ensure organ health.

Precautions During Treatment

Surgery: You must stop taking fruquintinib at least 2 weeks before any surgery and wait 2 weeks after surgery before starting again, as it can slow down wound healing.
Birth Control: Both men and women should use effective birth control during treatment and for several weeks after the last dose, as the drug can harm an unborn baby.

“Do’s and Don’ts” List

Do monitor your blood pressure at home every day and keep a log.
Do tell your doctor immediately if you have a severe headache, confusion, or vision changes.
Do swallow the capsules whole; do not crush or open them.
Don’t take a double dose if you miss a dose; just take the next dose at the regular time.
Don’t ignore any unusual bleeding, such as nosebleeds or blood in your stool.

Legal Disclaimer

Standard Medical Disclaimer: This guide is for informational purposes only and does not constitute medical advice. Fruquintinib is a prescription medication with serious potential risks. Always consult with a licensed oncologist or healthcare professional to discuss treatment options, risks, and benefits specific to your medical history. This content is based on medical data available as of 2026.